{"prompt": "['Product: MK-3475', '83', 'Protocol/Amendment No.: 604-09', 'RECIST 1.1', 'at', '1 radiologic (imaging)', 'evidence of PD', 'assessed by site', 'Site submits all required tumor imaging', 'to Blinded Independent Central Review (BICR)*', 'YES= BICR provides', 'BICR quality', 'email notice of', 'NO=BICR queries', 'check-- do', 'verification of PD in', 'images PASS?', '3-5 business days', 'NO=PD not verified', 'YES=PD is verified', 'Does BICR', 'Subject should', 'Subject may', 'remain on trial', 'verify PD per', 'remain on trial', 'RECIST : 1.1?', 'treatment', 'treatment per site PI', 'Subject to resume', 'Repeat tumor', 'imaging schedule', 'imaging at 4 weeks', 'per protocol,', 'if clinically indicated', 'NO=Site DOES NOT', 'Does SITE', 'YES=Site', 'confirm PD', 'confirm PD per', 'confirms', 'irRECIST', 'per', 'PD by irRECIST', 'irRECIST?', 'irRECIST', '1.Subject discontinues trial', '1. Subject MAY remain on study drug at', 'treatment...UPON', \"site Pl's discretion.\", 'sponsor consultation -', '2. Regular tumor imaging is followed;', 'exception is possible', 'unscheduled imaging should be', '2. Tumor imaging done,', 'obtained, if clinically indicated', 'ONLY if needed for End of', 'manage subject by irRECIST', 'Treatment (if previous', '3. Submit all tumor imaging to BICR', 'scan was done > 4 weeks)', 'Abbreviations: BICR=blinded independent central review, irRECIST=immune-related Response Evaluation', 'Criteria in Solid Tumors, PD=progressive disease, PI=principal investigator, RECIST=Response Evaluation', 'Criteria in Solid Tumors', \"*If subject is clinically stable, may continue study treatment at the local site investigator's discretion while\", 'awaiting verification of PD per RECIST 1.1 by BICR and/or confirmatory tumor imaging by site by irRECIST.', 'Figure 2 Imaging and Treatment for Clinically Stable Subjects After First Radiologic', 'Evidence of PD Assessed by the Site', '7.1.2.8 Tumor Tissue Collection: PD-L1 Status', 'Participation in this trial will be dependent upon supplying tumor tissue for PD-L1 testing', 'from locations not radiated prior to biopsy. Subjects whose submitted tissue is not evaluable', 'for PD-L1 status can still be eligible to participate in the study.', 'MK-3475-604-09 Final Protocol', '23-Apr-2019', 'Confidential']['Product: MK-3475', '84', 'Protocol/Amendment No.: 604-09', 'All subjects should submit either a newly obtained core or excisional biopsy or archival', 'tissue (fine needle aspiration [FNA], endobronchial ultrasound [EBUS], guided', 'transbronchial needle aspiration [TBNA], cell pellets, cytology, and blood smears are not', 'adequate for both archival and new tissue samples) to a central laboratory for', 'characterization of PD-L1 status prior to treatment allocation.', 'Note: Submission of formalin-fixed paraffin embedded tumor tissue sample blocks are', 'preferred; if submitting unstained slides, the slides should be freshly cut and submitted to the', 'testing laboratory within 14 days from the site slide section date, otherwise a new specimen', 'will be requested.', 'If the sample is determined to be non-evaluable prior to testing by the central laboratory, a', 'new sample should be submitted if available. This may include additional cut slides that are', 'outside of the 14-day window noted above.', 'Individual subject PD-L1 status will not be disclosed to investigative sites and study subjects.', 'Analyses by PD-L1 biomarker status will be limited and documented.', 'If the subject signs the Future Biomedical Research consent, any leftover samples that would', 'be ordinarily discarded at the end of the main study will be retained for Future Biomedical', 'Research.', '7.1.3 Laboratory Procedures/Assessments', 'Details regarding specific laboratory procedures/assessments to be performed in this trial are', 'provided below. The total amount of blood/tissue to be drawn/collected over the course of', 'the trial (from pre-trial to post-trial visits), including approximate blood/tissue volumes', 'drawn/collected by visit and by sample type per subject can be found in the Laboratory', 'Manual. Refer to the Trial Flow Chart (Section 6.0) for the timing of laboratory assessments.', '7.1.3.1 Clinical Laboratory Evaluations', 'Clinical laboratory tests are specified in Table 9.', 'MK-3475-604-09 Final Protocol', '23-Apr-2019', 'Confidential']\n\n###\n\n", "completion": "END"}